Clinical Trial Update: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating the combination of lurbinectedin and pembrolizumab in small cell lung cancer. The study's Phase 1 and Phase 2 portions have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Zepzelca (lurbinectedin)

Snippet

Sponsor: Antonio Calles Blanco | Conditions: Small Cell Lung Carcinoma | Phase 1, Phase 2 | Status: COMPLETED